Can you gain weight on Wegovy, and why does it happen?

What STEP 1 tells us about the full range of responses

The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with obesity and tracked them over 68 weeks. The headline figure (roughly 15% average body-weight reduction at 2.4mg) is real, but it is a mean across a wide distribution. Some participants lost considerably more; others lost very little; and a small subset either maintained weight or registered a net gain. That is not a failure of the trial design. It reflects the biological reality that GLP-1 receptor agonists do not work identically in everyone. Gut-hormone sensitivity, baseline metabolic rate, concurrent medications and adherence to the titration schedule all shape outcomes. If you are asking whether it is possible not to lose weight on Wegovy, the honest answer drawn from that evidence is yes, rarely during active treatment at the correct dose, but not never.

Reporting your progress to a prescriber matters precisely because of this range. If weight loss has stalled or reversed after several weeks at a given dose, that is clinical information, not a reason for embarrassment. Our guide to Wegovy covers the full licensed titration pathway and what monitoring looks like in practice.

Why weight sometimes increases during Wegovy treatment

Three patterns account for most in-treatment weight gain. First, the starting dose. Semaglutide begins at 0.25mg, a tolerability step, not a therapeutic level. Appetite suppression at that dose is modest, and if someone also reduces activity because of early nausea, calorie balance can tip the wrong way temporarily. This usually corrects itself as the dose escalates, but it can look alarming in the first month. Second, tolerance without titration. If dose increases are delayed or skipped, some people find the appetite effect plateaus; without a reduction in energy intake to match, weight drifts upward. Third, external factors. Stress-related eating, certain co-prescribed medicines, hormonal changes and life disruption can all override the appetite signal. A long bank-holiday weekend or a particularly difficult month at work are not abstract risks, they are the texture of real treatment. That is why aftercare and regular clinical check-ins exist.

Questions about medicines that interact with Wegovy often surface here; some co-prescriptions are associated with weight gain independently of semaglutide. A prescriber can weigh up the full picture.

Regain after stopping: what the evidence actually shows

This is where the clinical evidence is clearest and most important to read carefully. A follow-up study to STEP 1 (the STEP 1 extension) tracked participants for one year after they stopped semaglutide. Within twelve months, two-thirds of the weight lost had returned. By the end of that year, cardiometabolic markers such as blood pressure, blood-sugar levels and waist circumference had also largely reverted toward baseline. The NHS semaglutide medicines page is clear that this medicine is a long-term treatment; stopping it without a plan (rather than completing a managed course) is associated with significant rebound.

This is not unique to semaglutide. It reflects how obesity works as a chronic condition: the biological drives toward a higher set-point reassert themselves once the pharmacological signal is removed. Whether to continue, pause or stop is a clinical decision, not one to make because a supply chain hiccup lasted three weeks or the cost felt daunting that month. The evidence on post-Wegovy weight gain and what helps slow it is covered in more detail separately. And if you have concerns about what happens when treatment ends, that is exactly the kind of conversation our clinical team is set up for.

When weight gain on Wegovy needs clinical review

Not every plateau is the same thing. A two-week stall during dose titration is normal physiology. If you are noticing a consistent upward trend and wondering whether it is normal to gain weight on Wegovy, that question has a nuanced answer depending on where you are in the titration schedule. NICE's appraisal of semaglutide (TA875) includes a stopping criterion: if less than 5% of starting weight has been lost after six months at the maintenance dose, the prescriber should review whether to continue. That threshold exists to protect patients from indefinite exposure to a medicine that is not working for them, not to penalise slow starters.

Practical signs that warrant a conversation sooner: consistent weight increase over four or more weeks, new or changed medications that might be contributing, significant changes in eating patterns driven by mood rather than hunger, or a dose that has not escalated because of persistent side effects. Our page on gaining weight on Wegovy explores these scenarios and what options are available if this happens to you. If you are weighing up how Wegovy compares with other licensed options, a read of what is available for weight management can help frame that. And if you are wondering whether your situation might suit treatment at all, check your eligibility with our prescribers, there is no charge for the consultation.